In a groundbreaking recommendation, the National Comprehensive Cancer Network (NCCN) has broadened the scope of prostate cancers that qualify for active surveillance in the United States to include ...
Men diagnosed with nonmetastatic low- and intermediate-risk prostate cancer up to 6 times more likely to die of other causes. HealthDay News — Men with nonmetastatic prostate cancer receiving ...
Patients with nonmetastatic prostate cancer are more likely to die from other causes than from cancer when treated per guidelines. The 15-year cancer mortality risk is 5.5% for low-risk and 22% for ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...
Patients who receive guideline-concordant treatment for nonmetastatic prostate cancer are more likely to die from other causes. Men with nonmetastatic prostate cancer (PCa) who receive treatment ...
The NCCN's new resource educates patients on genetic testing for hereditary cancer risk, focusing on breast, ovarian, pancreatic, and prostate cancers. Advances in genetic technology, spurred by the ...
Credit: Getty Images Large language models leverage transformed architecture to extract and summarize unstructured electronic health record data, enabling automated retrieval of clinically relevant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback